Molecular Partners AG

As of June 30, 2026, Molecular Partners AG carries a market capitalization of 129.66M, placing it among publicly traded companies globally. Its enterprise value stands at 59.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Molecular Partners AG's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Molecular Partners AG has 38.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Molecular Partners AG maintains a current ratio of 7.27, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.20, indicating elevated leverage, while an interest coverage ratio of -2,258.05 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Molecular Partners AG posted a negative return on equity (ROE) of -61.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.20, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 155.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Molecular Partners AG recorded 4,334.08 in income tax expense. The company reported a pretax loss of -55.46M and -55.47M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Molecular Partners AG's stock has gained approximately 7.39% over the past 52 weeks. The 50-day moving average sits at 3.56, while the 200-day moving average is 3.58.

Over the twelve months ended June 30, 2026, Molecular Partners AG generated - - in revenue and converted that into -55.47M in net income, yielding earnings per share of -1.47. EBITDA reached -53.83M, while operating income came in at -55.94M.

As of June 30, 2026, Molecular Partners AG holds 73.60M in cash and equivalents against 3.30M in total debt, resulting in a net debt position of -73.60M. Total book value stands at 63.43M, with working capital of 66.76M providing operational flexibility.

Molecular Partners AG produced -49.96M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -205,868.81 in capital expenditures, free cash flow totaled -50.17M - equivalent to -1.33 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -39.36: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.92, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Molecular Partners AG shareholders.

As of June 30, 2026, Molecular Partners AG has an Altman Z-Score of -3.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.